$KIDS
OrthoPediatrics Corp

2018 Q4 Form 10-Q Financial Statement

#000142545018000115 Filed on October 31, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $14.57M $15.82M $12.38M
YoY Change 24.72% 27.84% 22.1%
Cost Of Revenue $4.050M $3.843M $9.491M
YoY Change -54.14% -59.51% 32.61%
Gross Profit $10.51M $11.98M $9.491M
YoY Change 19.04% 26.19% 32.61%
Gross Profit Margin 72.17% 75.71% 76.69%
Selling, General & Admin $11.10M $12.03M $9.120M
YoY Change -8.26% 31.88% 27.04%
% of Gross Profit 105.57% 100.42% 96.09%
Research & Development $1.280M $1.122M $1.127M
YoY Change 36.17% -0.44% 124.95%
% of Gross Profit 12.17% 9.37% 11.87%
Depreciation & Amortization $710.0K $780.0K $660.0K
YoY Change 7.58% 18.18% 32.0%
% of Gross Profit 6.75% 6.51% 6.95%
Operating Expenses $12.38M $13.15M $10.25M
YoY Change -5.06% 28.32% 33.42%
Operating Profit -$1.866M -$1.172M -$754.0K
YoY Change -55.61% 55.44% 43.89%
Interest Expense -$530.0K -$610.0K $761.0K
YoY Change -15.87% -180.16% 90.73%
% of Operating Profit
Other Income/Expense, Net -$70.00K -$693.0K -$781.0K
YoY Change 600.0% -11.27% 142.55%
Pretax Income -$2.470M -$1.870M -$1.540M
YoY Change -49.07% 21.43% 81.18%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.468M -$1.865M -$1.536M
YoY Change -49.06% 21.42% 81.56%
Net Earnings / Revenue -16.94% -11.79% -12.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$189.7K -$148.2K -$127.9K
COMMON SHARES
Basic Shares Outstanding 12.81M shares 12.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.70M $24.50M $2.200M
YoY Change 42.49% 1013.64%
Cash & Equivalents $60.69M $24.46M $2.238M
Short-Term Investments
Other Short-Term Assets $1.300M $1.000M $1.900M
YoY Change 62.5% -47.37%
Inventory $25.71M $26.90M $19.00M
Prepaid Expenses
Receivables $8.999M $9.456M $5.686M
Other Receivables $500.0K $0.00 $0.00
Total Short-Term Assets $97.16M $61.84M $28.89M
YoY Change 39.67% 114.06%
LONG-TERM ASSETS
Property, Plant & Equipment $12.77M $12.77M $9.749M
YoY Change 22.88% 31.03%
Goodwill $0.00
YoY Change
Intangibles $2.181M $2.260M $2.443M
YoY Change -7.15% -7.49%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.181M $15.03M $12.19M
YoY Change -82.88% 23.31%
TOTAL ASSETS
Total Short-Term Assets $97.16M $61.84M $28.89M
Total Long-Term Assets $2.181M $15.03M $12.19M
Total Assets $112.1M $76.88M $41.08M
YoY Change 36.21% 87.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.971M $5.903M $5.102M
YoY Change -27.73% 15.7%
Accrued Expenses $3.600M $3.300M $2.300M
YoY Change 24.14% 43.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $118.0K $117.0K $111.0K
YoY Change 4.42% 5.41%
Total Short-Term Liabilities $9.217M $10.92M $10.42M
YoY Change -2.64% 4.8%
LONG-TERM LIABILITIES
Long-Term Debt $21.16M $25.28M $27.50M
YoY Change -16.51% -8.08%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $21.16M $25.28M $27.50M
YoY Change -16.51% -8.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.217M $10.92M $10.42M
Total Long-Term Liabilities $21.16M $25.28M $27.50M
Total Liabilities $30.37M $36.19M $37.90M
YoY Change -12.74% -4.51%
SHAREHOLDERS EQUITY
Retained Earnings -$115.1M -$112.6M -$82.22M
YoY Change 0.0% 36.98%
Common Stock $4.000K $2.000K $1.000K
YoY Change 100.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $81.73M $40.69M -$72.49M
YoY Change
Total Liabilities & Shareholders Equity $112.1M $76.88M $41.08M
YoY Change 36.21% 87.13%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$2.468M -$1.865M -$1.536M
YoY Change -49.06% 21.42% 81.56%
Depreciation, Depletion And Amortization $710.0K $780.0K $660.0K
YoY Change 7.58% 18.18% 32.0%
Cash From Operating Activities -$2.720M -$1.190M $340.0K
YoY Change -18.32% -450.0% -361.54%
INVESTING ACTIVITIES
Capital Expenditures $50.00K -$1.160M -$2.150M
YoY Change -104.0% -46.05% 76.23%
Acquisitions
YoY Change
Other Investing Activities -$500.0K
YoY Change
Cash From Investing Activities -$460.0K -$1.160M -$2.150M
YoY Change -63.2% -46.05% 76.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 39.42M 300.0K 1.810M
YoY Change -12.24% -83.43% 22.3%
NET CHANGE
Cash From Operating Activities -2.720M -1.190M 340.0K
Cash From Investing Activities -460.0K -1.160M -2.150M
Cash From Financing Activities 39.42M 300.0K 1.810M
Net Change In Cash 36.24M -2.050M 0.0000000002910
YoY Change -10.16% -704374636543999900.0% -100.0%
FREE CASH FLOW
Cash From Operating Activities -$2.720M -$1.190M $340.0K
Capital Expenditures $50.00K -$1.160M -$2.150M
Free Cash Flow -$2.770M -$30.00K $2.490M
YoY Change 33.17% -101.2% 128.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
ORTHOPEDIATRICS CORP
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Type
DocumentType
10-Q
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12811450 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001425450
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
CY2018Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
131000 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
143000 USD
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00025
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00025
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12807520 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12621781 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12807520 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12621781 shares
CY2018Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2017Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2018Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2017Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
kids Classof Warrantor Right Term
ClassofWarrantorRightTerm
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24463000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9557000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
kids Classof Warrantor Right Term
ClassofWarrantorRightTerm
P10Y
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1865000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1537000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9557000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4087000 USD
CY2018Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2017Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1484000 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4364000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1865000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3021000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8451000 USD
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42582000 USD
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9456000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5603000 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1045000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
831000 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
61844000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
69561000 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12774000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10391000 USD
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2089000 USD
CY2018Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
260000 USD
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
260000 USD
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2260000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2349000 USD
CY2018Q3 us-gaap Assets
Assets
76878000 USD
CY2017Q4 us-gaap Assets
Assets
82301000 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5903000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5495000 USD
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3302000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2905000 USD
CY2018Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
117000 USD
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
113000 USD
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1594000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
954000 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10916000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9467000 USD
CY2018Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
21330000 USD
CY2017Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
21418000 USD
CY2018Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
3947000 USD
CY2017Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
3921000 USD
CY2018Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25277000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25339000 USD
CY2018Q3 us-gaap Liabilities
Liabilities
36193000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
34806000 USD
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153649000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
150424000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112623000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103066000 USD
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-343000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
135000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
40685000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
47495000 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76878000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82301000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15820000 USD
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12375000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42991000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33939000 USD
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3843000 USD
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2884000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10825000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8321000 USD
CY2018Q3 us-gaap Gross Profit
GrossProfit
11977000 USD
CY2017Q3 us-gaap Gross Profit
GrossProfit
9491000 USD
us-gaap Gross Profit
GrossProfit
32166000 USD
us-gaap Gross Profit
GrossProfit
25618000 USD
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7150000 USD
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5633000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20005000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15122000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4877000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3487000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16393000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10282000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1122000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1127000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3455000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2482000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
13149000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
10247000 USD
us-gaap Operating Expenses
OperatingExpenses
39853000 USD
us-gaap Operating Expenses
OperatingExpenses
27886000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1172000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-756000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7687000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2268000 USD
CY2018Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-608000 USD
CY2017Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-761000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1722000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1857000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-85000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-148000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-693000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-781000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1870000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1819000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1865000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1537000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9557000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4087000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1865000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3021000 USD
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9557000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8451000 USD
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12624858 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1773385 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12417972 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1754576 shares
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.70
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.82
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1865000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1537000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9557000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4087000 USD
CY2018Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-100000 USD
CY2017Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
121000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-478000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
193000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-100000 USD
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
121000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-478000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1965000 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1416000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10035000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3894000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
47495000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9557000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-478000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
326000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2899000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
40685000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9557000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4087000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2177000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1748000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2899000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1081000 USD
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
4077000 USD
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
1588000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
214000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
382000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
408000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1559000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
798000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
513000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
15000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-193000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12855000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3894000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
195000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1337000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5311000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3949000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5506000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5286000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10139000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
84000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
80000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
326000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
250000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9809000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18119000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
629000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42582000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1609000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24463000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2238000 USD
us-gaap Interest Paid Net
InterestPaidNet
1722000 USD
us-gaap Interest Paid Net
InterestPaidNet
1856000 USD
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
0 USD
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4364000 USD
kids Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
1061000 USD
kids Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
1196000 USD
us-gaap Nature Of Operations
NatureOfOperations
BUSINESS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:4.22pt;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, Bandloc, Pediguard and Pediatric Nailing Platform | Femur, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand permitting us to sell under an agency model direct to local hospitals in these countries. Operations began in the United Kingdom on April 3, 2017, in Australia on May 1, 2017 and in New Zealand on July 1, 2017. In September 2018, we further expanded operations in Canada selling direct to local hospitals. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">On October 12, 2017, we completed an initial public offering ("IPO") of our common stock, in which we issued and sold 4,600,000 shares of common stock at a public offering price of $13.00 per share for aggregate gross proceeds of $59,800. We received approximately $46,900 in net proceeds after deducting $4,200 of underwriting discounts and commissions, paying approximately $2,700 of offering costs and paying approximately $6,000 of Series B dividends. </span></div>Our largest investor is Squadron Capital LLC (“Squadron”), a family office firm headquartered near Hartford, Connecticut.
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112623000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103066000 USD
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
CY2018Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2018Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1122000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1127000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3455000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2482000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q3 us-gaap Long Term Debt
LongTermDebt
25394000 USD
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
25452000 USD
CY2018Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
117000 USD
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
113000 USD
CY2018Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25277000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25339000 USD
us-gaap Royalty Expense
RoyaltyExpense
108000 USD
us-gaap Royalty Expense
RoyaltyExpense
111000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
70335000 USD
CY2017Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
335000 USD
CY2018Q3 kids Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation
OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation
16200000 USD
CY2018Q3 kids Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit
OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit
1062000 USD
CY2018Q3 kids Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase
OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease
2302000 USD
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
176959 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.42
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11533 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
29.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
50652 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
27.61
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
114774 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y1M6D
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
44101 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
27.03
kids Class Of Warrant Or Right Forfeited Or Expired
ClassOfWarrantOrRightForfeitedOrExpired
25535 shares
kids Class Of Warrant Or Right Forfeited Or Expired Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightForfeitedOrExpiredWeightedAverageExercisePriceOfWarrantsOrRights
26.55
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18566 shares
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
27.69
CY2018Q3 kids Classof Warrantor Right Exercised
ClassofWarrantorRightExercised
0 shares
CY2018Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2017Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1484000 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1865000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1537000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9557000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4087000 USD
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4364000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1865000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3021000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9557000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8451000 USD
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12624858 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1773385 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12417972 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1754576 shares
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.70
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.82
CY2018Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
307881 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4576109 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2018Q3 us-gaap Revenues
Revenues
15820000 USD
CY2017Q3 us-gaap Revenues
Revenues
12375000 USD
us-gaap Revenues
Revenues
42991000 USD
us-gaap Revenues
Revenues
33939000 USD
CY2018Q3 us-gaap Revenues
Revenues
15820000 USD
CY2017Q3 us-gaap Revenues
Revenues
12375000 USD
us-gaap Revenues
Revenues
42991000 USD
us-gaap Revenues
Revenues
33939000 USD
CY2018Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
kids Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment
ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment
500000 USD

Files In Submission

Name View Source Status
0001425450-18-000115-index-headers.html Edgar Link pending
0001425450-18-000115-index.html Edgar Link pending
0001425450-18-000115.txt Edgar Link pending
0001425450-18-000115-xbrl.zip Edgar Link pending
exhbit322-cfocertifica.htm Edgar Link pending
exhibit311-ceocertific.htm Edgar Link pending
exhibit312-cfocertific.htm Edgar Link pending
exhibit321-ceocertific.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kids-20180930.htm Edgar Link pending
kids-20180930.xsd Edgar Link pending
kids-20180930_cal.xml Edgar Link unprocessable
kids-20180930_def.xml Edgar Link unprocessable
kids-20180930_htm.xml Edgar Link completed
kids-20180930_lab.xml Edgar Link unprocessable
kids-20180930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending